Intelligence Feed event · Macro · 2026-09-06

    Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand

    Question

    Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand

    Direct answer

    Market research from SNS Insider projects the global atopic dermatitis therapeutic market will expand from $15.92 billion in 2025 to $33.42 billion by 2035, reflecting a 7.70% compound annual growth rate over the ten-year period. Therapeutic adoption is transitioning rapidly from topical corticosteroids toward targeted biologic therapies and JAK inhibitors. North America maintains the largest regional revenue share at 36%, while Asia-Pacific is projected to exhibit the highest rate of prescription growth. The forecast reinforces multi-year revenue runway expectations for established immunology leaders including Regeneron, Sanofi, AbbVie, and Eli Lilly as combination regimens and second-generation indications roll out.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand”, revision 1, evidence through 2026-09-06. https://marketontology.com/market-events/2026-09-06/atopic-dermatitis-market-projected-to-reach-33-42b-by-2035-on-biologics-demand-7a4309

    MACRO
    Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
    Market research from SNS Insider projects the global atopic dermatitis therapeutic market will expand from $15.92 billion in 2025 to $33.42 billion by 2035, reflecting a 7.70% compound annual growth rate over the ten-year period. Therapeutic adoption is transitioning rapidly from topical corticosteroids toward targeted biologic therapies and JAK inhibitors. North America maintains the largest regional revenue share at 36%, while Asia-Pacific is projected to exhibit the highest rate of prescription growth. The forecast reinforces multi-year revenue runway expectations for established immunology leaders including Regeneron, Sanofi, AbbVie, and Eli Lilly as combination regimens and second-generation indications roll out.
    REGNABBVLLY
    Impact
    61
    SEP 6
    SIG
    80%
    REGNABBVLLY
    Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics Demand
    Market research from SNS Insider projects the global atopic dermatitis therapeutic market will expand from $15.92 billion in 2025 to $33.42 billion by 2035, reflecting a 7.70% compound annual growth rate over the ten-year period. Therapeutic adoption is transitioning rapidly from topical corticosteroids toward targeted biologic therapies and JAK inhibitors. North America maintains the largest regional revenue share at 36%, while Asia-Pacific is projected to exhibit the highest rate of prescription growth. The forecast reinforces multi-year revenue runway expectations for established immunology leaders including Regeneron, Sanofi, AbbVie, and Eli Lilly as combination regimens and second-generation indications roll out.
    → Accelerated clinical adoption of targeted biologic therapies expands top-line franchise revenues and margins for primary market share holders Regeneron and Sanofi.
    Impact
    Market research from SNS Insider projects the global atopic dermatitis therapeutic market will expand from $15.92 billion in 2025 to $33.42 billion by 2035, reflecting a 7.70% compound annual growth rate over the ten-year period. Therapeutic adoption is transitioning rapidly from topical corticosteroids toward targeted biologic therapies and JAK inhibitors. North America maintains the largest regional revenue share at 36%, while Asia-Pacific is projected to exhibit the highest rate of prescription growth. The forecast reinforces multi-year revenue runway expectations for established immunology leaders including Regeneron, Sanofi, AbbVie, and Eli Lilly as combination regimens and second-generation indications roll out.
    Affected
    REGNABBVLLY
    Transmission
    Accelerated clinical adoption of targeted biologic therapies expands top-line franchise revenues and margins for primary market share holders Regeneron and Sanofi.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    REGNimmunology franchise revenue expansion via Dupixent market shareUp1-3mSource identifies REGN among primary market leaders in atopic dermatitis biologics.
    ABBVJAK inhibitor prescription volume growthUp1-3mSource names AbbVie as a major market participant in novel dermatitis therapies.
    LLYdermatology immunology pipeline revenue growthUp1-3mSource highlights Eli Lilly immunology market exposure.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month